The diagnostic value of p63, p16, and p53 immunohistochemistry in distinguishing seborrheic keratosis, actinic keratosis, and Bowen's disease.
Bowen's Disease
/ diagnosis
Cyclin-Dependent Kinase Inhibitor p16
/ analysis
Humans
Immunohistochemistry
Keratosis, Actinic
/ diagnosis
Keratosis, Seborrheic
/ diagnosis
Skin Neoplasms
/ diagnosis
Transcription Factors
/ analysis
Tumor Suppressor Protein p53
/ analysis
Tumor Suppressor Proteins
/ analysis
Actinic keratosis
Bowen's disease
Immunohistochemistry
P16
Seborrheic keratosis
p53
p63
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
20
12
2020
received:
12
11
2020
accepted:
17
01
2021
pubmed:
27
1
2021
medline:
26
5
2021
entrez:
26
1
2021
Statut:
ppublish
Résumé
Seborrheic keratosis (SK), actinic keratosis (AK), and Bowen's disease (BD) are squamoproliferative disorders of the skin. Histologically, they may mimic each other and therefore, they might be misinterpreted, especially in small samples. The aim of this study is to clarify the expression of p63, p16, and p53 proteins in SK, AK, and BD and evaluate the efficacy of these markers in order to distinguish between the aforementioned lesions. A total of 46 cases were collected (15 SK, 16 AK, and 15 BD) and stained for p63, p16, and p53. The stain intensity and the cell distribution labeling were scored and then analyzed by SPSS software. All cases of BD which became positive for p53 revealed basal keratinocytes sparing. Instead, all or nearly all basal keratinocytes in AK cases were positive for this marker. These were also seen in p16 staining results and they were between AK and BD (P = .024). Our study demonstrates p16 and p53 are useful markers in separating AK and BD according to basal keratinocytes involvement and sparing, respectively.
Substances chimiques
CDKN2A protein, human
0
Cyclin-Dependent Kinase Inhibitor p16
0
TP53 protein, human
0
TP63 protein, human
0
Transcription Factors
0
Tumor Suppressor Protein p53
0
Tumor Suppressor Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14817Subventions
Organisme : Skin Research Center, Shahid Beheshti Medical University of Sciences, Tehran, Iran
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Patterson JW. Tumors of the Epidermis. Weedon's Skin Pathology. Charlottesville, VA: ELSEVIER; 2020:833-836.
Patterson JW. Tumors of the Epidermis. Weedon's Skin Pathology. Charlottesville, VA: ELSEVIER; 2020:840-843.
Patterson JW. Tumors of the Epidermis. Weedon's Skin Pathology. Charlottesville, VA: ELSEVIER; 2020:844-847.
Missero C, Antonini D. Crosstalk among p53 family members in cutaneous carcinoma. Exp Dermatol. 2014;23(3):143-146. https://doi.org/10.1111/exd.12320.
Bäckvall H, Wolf O, Hermelin H, et al. The density of epidermal p53 clones is higher adjacent to squamous cell carcinoma in comparison with basal cell carcinoma. Br J Dermatol. 2004;150(2):259-266. https://doi.org/10.1111/j.1365-2133.2004.05683.x.
Maltzman W, Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol. 1984;4(9):1689-1694. https://doi.org/10.1128/mcb.4.9.1689.
Hao Z-F, Ao JH, Su YM, et al. ATF3 activates Stat3 phosphorylation through inhibition of p53 expression in skin cancer cells. Asian Pacific J Cancer Prev. 2013;14(12):7439-7444. https://doi.org/10.7314/apjcp.2013.14.12.7439.
Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90(4):809-819. https://doi.org/10.1016/s0092-8674(00)80540-1.
Brown RA, Kim J. Evaluation of invasive squamous cell carcinoma, Seborrheic keratosis and verruca vulgaris in superficial shave biopsies using p16, p53, p63, and PHLDA1 immunohistochemistry. J Clin Exp Dermatol Res. 2016;7(352):2. https://doi.org/10.4172/2155-9554.1000352.
Smirnov A, Anemona L, Novelli F, et al. p63 is a promising marker in the diagnosis of unusual skin cancer. Int J Mol Sci. 2019;20(22):5781. https://doi.org/10.3390/ijms20225781.
Hodges A, Smoller BR. Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin. Mod Pathol. 2002;15(11):1121-1125. https://doi.org/10.1097/01.MP.0000032536.48264.D1.
Abbas O, Richards JE, Yaar R, et al. Stem cell markers (cytokeratin 15, cytokseratin 19 and p63) in in situ and invasive cutaneous epithelial lesions. Mod Pathol. 2011;24(1):90-97.
Kalegowda IY, Böer-Auer A. Clonal seborrheic keratosis versus pagetoid Bowen disease: histopathology and role of adjunctive markers. Am J Dermatopathol. 2017;39(6):433-439.
Harvey NT, Leecy T, Wood BA. Immunohistochemical staining for p16 is a useful adjunctive test in the diagnosis of Bowen's disease. Pathology. 2013;45(4):402-407.
Omman RA, Speiser J, Robinson S, et al. Clonal highlights: clonal seborrheic keratoses often demonstrates p16 expression. J Cutan Pathol. 2019;46(6):411-417.
Alexandrova AK, Smolyannikova VA, Filatova VA, et al. Protein p16 role in seborrheic keratosis. Our Dermatol Online. 2016;7(4):377.
Ko C, Srisuttiyakorn C. Atypical intraepidermal keratinocytic lesions falling short of carcinoma in situ (Bowen disease) on routine staining: the utility of p16 immunostaining. J Cutan Pathol. 2014;41(12):975-977.
Bagazgoitia L, Cuevas J, Juarranz A. Expression of p53 and p16 in actinic keratosis, bowenoid actinic keratosis and Bowen's disease. J Eur Acad Dermatol Venereol. 2010;24(2):228-230.
Salama ME, Mahmood MN, Qureshi HS, et al. p16INK4a expression in actinic keratosis and Bowen's disease. Br J Dermatol. 2003;149(5):1006-1012.
Kim KH, Park EJ, Seo YJ, et al. Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors. J Dermatol. 2006;33(5):319-325.
Mortier L, Marchetti P, Delaporte E, et al. Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16INK4a tumor suppressor. Cancer Lett. 2002;176(2):205-214.
Rakocevic M, Jovicic BP, Jocic T, et al. Interplay between the immunohistochemical expression of p53 and the proliferation index in the keratinocyte tumors of the skin. Serbian J Exp Clin Res. 2018;19(4):331-341.
Heerfordt IM, Nissen CV, Poulsen T, et al. Thickness of actinic keratosis does not predict dysplasia severity or P53 expression. Sci Rep. 2016;6(1):1-6.
Bakshi A, Shafi R, Nelson J, et al. The clinical course of actinic keratosis correlates with underlying molecular mechanisms. Br J Dermatol. 2020;182(4):995-1002.
Ishida H, Kumakiri M, Ueda K, et al. Comparative histochemical study of Bowen's disease and actinic keratosis: preserved normal basal cells in Bowen's disease. Eur J Histochem. 2009;45(2):177-190.
Ramzi ST, Maruno M, Khaskley NM, et al. An assessment of the malignant potential of actinic keratoses and Bowen's disease: p53 and PCNA expression pattern correlate with the number of desmosomes. J Dermatol. 2002;29(9):562-572.
Charpentier E, Lavker RM, Acquista E, et al. Plakoglobin suppresses epithelial proliferation and hair growth in vivo. J Cell Biol. 2000;149(2):503-520.